2083. Glucocorticoid sparing effect of Janus kinase inhibitors compared to biologic disease modifying anti-rheumatic drugs in rheumatoid arthritis, a single-centre retrospective analysis.
作者: Giovanni Adami.;Riccardo Bixio.;Giulia Virelli.;Isotta Galvagni.;Francesca Mastropaolo.;Andrea Morciano.;Francesca Ruzzon.;Valeria Messina.;Elena Fracassi.;Davide Gatti.;Ombretta Viapiana.;Antonio Carletto.;Maurizio Rossini.
来源: Rheumatology (Oxford). 2025年64卷4期1698-1704页
Glucocorticoid sparing in rheumatoid arthritis (RA) treatment is crucial to minimizing adverse effects associated with long-term use. Janus kinase inhibitors (JAKi) could potentially offer a more potent glucocorticoid-sparing effect than biologic DMARDs (bDMARDs).
2084. Incidence of chronic recurrent multifocal osteomyelitis in children and adolescents in the UK and Republic of Ireland.
作者: Daphne Theresa Chia.;Andoni Paul Toms.;Anish Sanghrajka.;Athimalaipet V Ramanan.;Orla G Killeen.;Cristina Ilea.;Kamran Mahmood.;Sandrine Compeyrot-Lacassagne.;Kathryn Bailey.;Neil Martin.;Kate Armon.;Chenqu Suo.
来源: Rheumatology (Oxford). 2025年64卷4期2162-2170页
Chronic recurrent multifocal osteomyelitis (CRMO), also known as chronic non-bacterial osteomyelitis (CNO), is a rare autoinflammatory condition affecting the bones in children and teenagers. The actual incidence of CRMO remains uncertain. The objective of this study was to identify the incidence of CRMO in children and young people under the age of 16 years in the United Kingdom (UK) and Republic of Ireland (ROI). We also aimed to delineate the demographics, clinical presentation, investigations, initial management and healthcare needs for children and adolescents with CRMO.
2085. Identifying enthesitis in the sacroiliac joints in patients with axial spondyloarthritis by readers of varying experience: impact of the learning progress.
作者: Dong Liu.;Jiaoshi Zhao.;Churong Lin.;Budian Liu.;Jinwei Li.;Yuxuan Zhang.;Ou Jin.;Jieruo Gu.
来源: BMC Rheumatol. 2024年8卷1期36页
This study aimed to investigate the accuracy of identifying enthesitis along with other inflammatory lesions and structural lesions on the MRI of the sacroiliac joints (SIJ) by readers of varying experience and how training sessions and workshops could help improve the accuracy.
2087. Pregnancy outcome predictors in systemic lupus erythematosus: a systematic review and meta-analysis.
作者: Merlijn Wind.;Juan J Fierro.;Kitty W M Bloemenkamp.;Karina de Leeuw.;A Titia Lely.;Maarten Limper.;Marieke Sueters.;Y K Onno Teng.;Isabel J Walter.;Judith Kooiman.
来源: Lancet Rheumatol. 2024年6卷10期e667-e683页
To enhance patient-tailored preconception risk assessment for women with systemic lupus erythematosus (SLE), knowledge on risk factors associated with adverse pregnancy outcomes is required. Therefore, we did a systematic review and meta-analysis to identify and provide unambiguous effect sizes of preconception predictors of pregnancy outcomes in women with SLE.
2089. Comment on: Hydroxychloroquine levels in pregnancy and materno-fetal outcomes in Systemic Lupus Erythematosus patients: Reply.
作者: Gelsomina Alle.;Gaëlle Guettrot-Imbert.;Anna Molto.;Nathalie Costedoat-Chalumeau.; .
来源: Rheumatology (Oxford). 2025年64卷5期3203-3204页 2090. Hepatitis B reactivation in PsA patients: an SLR and meta-analysis for IL-17, IL-23 and JAK inhibitors.
作者: Theodoros Androutsakos.;Konstantinos Dimitriadis.;Maria-Loukia Koutsompina.;Konstantinos D Vassilakis.;Avraam Pouliakis.;George E Fragoulis.
来源: Rheumatology (Oxford). 2025年64卷3期935-942页
HBV reactivation (HBVr) constitutes a side effect of the treatment of autoimmune rheumatic diseases. Even though HBVr risk of conventional synthetic DMARDs (csDMARDs) and anti-tumor necrosis factor (anti-TNF) agents has long been established, the risk of targeted synthetic (ts)DMARDs and anti-interleukin (anti-IL) agents remains largely unknown.
2091. Multimodal imaging of structural damage and inflammation in psoriatic arthritis: a comparison of DMARD-naive and DMARD-failure patients.
作者: Nağme Ö Renkli.;Nienke J Kleinrensink.;Julia Spierings.;Simon Mastbergen.;Harald E Vonkeman.;Shasti C Mooij.;Lydia G Schipper.;Amin Herman.;Iris Ten Katen.;Frank J Nap.;Marjolein E Hol.;Pim A de Jong.;Mylène P Jansen.;Wouter Foppen.; .
来源: Rheumatology (Oxford). 2025年64卷4期1760-1769页
To compare inflammatory and structural differences in active PsA between DMARD-naive and DMARD-failure patients using diverse imaging approaches for future analyses. Additionally, to explore the influence of patient characteristics (clinical and demographic variables) on imaging findings.
2093. Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study.
作者: Francesco Muratore.;Chiara Marvisi.;Giulia Cassone.;Caterina Ricordi.;Luigi Boiardi.;Pamela Mancuso.;Giulia Besutti.;Lucia Spaggiari.;Massimiliano Casali.;Stefania Croci.;Rexhep Durmo.;Annibale Versari.;Gabriella Di Tommaso.;Mariagrazia Catanoso.;Paolo Giorgi Rossi.;Carlo Salvarani.
来源: Rheumatology (Oxford). 2025年64卷5期3057-3062页
To assess the maintenance of efficacy of one year of tocilizumab (TCZ) monotherapy after its discontinuation in large vessel-GCA (LV-GCA).
2095. Factors associated with long-term opioid use among patients with axial spondyloarthritis or psoriatic arthritis who initiate opioids.
作者: Yun-Ting Huang.;David A Jenkins.;Belay Birlie Yimer.;Meghna Jani.
来源: Rheumatology (Oxford). 2025年64卷4期1844-1852页
Up to one in five patients with axial spondyloarthritis (AxSpA) or psoriatic arthritis (PsA) newly initiated on opioids transition to long-term use within the first year. This study aimed to investigate individual factors associated with long-term opioid use among opioid new users with AxSpA/PsA.
2096. Evaluation of changes in cardiac longitudinal strain rate in patients with systemic sclerosis undergoing iloprost treatment: an observational study.
作者: Ivan Isaia.;Paola Aparo.;Federica Castelletti.;Matteo Regolo.;Maria Letizia Aprile.;Paolo Fiorenza.;Gianluca Sambataro.;Lorenzo Malatino.;Michele Colaci.
来源: Rheumatology (Oxford). 2025年64卷5期3063-3068页
SSc is characterized by widespread microangiopathy and fibrosis of skin and visceral organs. Left ventricle involvement is usually subclinical, characterized by systolic and/or diastolic dysfunction. The global longitudinal strain (GLS), a validated and reliable technique for the measurement of ventricular longitudinal deformation by means of echocardiography, may detect subclinical systolic dysfunction of SSc myocardium. The improvement of myocardial perfusion by means of intravenous Iloprost administration could ameliorate the contractility of SSc heart. Therefore, we aimed to evaluate GLS in a series of SSc patients prior and after Iloprost infusion.
2097. Subclinical psoriatic arthritis and disease interception-where are we in 2024?
作者: Clementina López-Medina.;Dennis McGonagle.;Laure Gossec.
来源: Rheumatology (Oxford). 2025年64卷1期56-64页
Psoriatic arthritis (PsA) is a chronic rheumatic disease that usually appears in patients with skin psoriasis, making it a model for detection of joint disease in the pre-clinical phases in a setting where therapy for cutaneous disease may ameliorate or prevent arthritis development. Such PsA prevention appears credible due to the increasingly recognized closely shared immunopathology between the skin and joints, especially the entheses. Recently, several initiatives have explored the concept of pre-clinical PsA, and nomenclatures have been developed with the recent EULAR nomenclature proposing a simplified three stages from psoriasis to clinical PsA development, namely at risk of PsA, subclinical PsA and early PsA. A better comprehension of early PsA and the identification of individuals predisposed to its development could enable interventions to 'prevent' the appearance of PsA. Several recent retrospective observational studies have demonstrated disease interception feasibility, i.e. treatment of people with psoriasis may prevent the appearance of PsA, in particular using biologic disease-modifying drugs. However, further data are urgently required due to unexpected findings in some studies where TNF inhibition for psoriasis does not reduce the rate of PsA development. In this review we address the current challenges in early PsA, including comparisons of pre-PsA nomenclature sets, its risk factors and the potential for disease interception.
2098. Benefits of a Juvenile Arthritis Support Program (JASP-1) for children recently diagnosed with Juvenile Idiopathic Arthritis and their parents.
作者: Karina Mördrup.;Johanna Granhagen Jungner.;Eva Broström.;Karin Palmblad.;Cecilia Bartholdson.
来源: BMC Rheumatol. 2024年8卷1期35页
Medical treatment for children with Juvenile Idiopathic Arthritis (JIA) has improved radically since the development of biological disease-modifying antirheumatic drugs. However, children suffer from pain and anxiety, and parents often experience loneliness and lack of support. Some parents reported that information provided at the time their child was diagnosed could be difficult to assimilate. Therefore, the aim of this study was to develop a Juvenile Arthritis Support Program (JASP-1) for children recently diagnosed with JIA and their parents. Moreover, the aim was to explore patients´ and parents´ experiences with JASP-1 and its potential impact on patients´ physical health.
2099. Infection versus disease activity in systemic lupus erythematosus patients with fever.
作者: Rasha A Abdel-Magied.;Nehal W Mokhtar.;Noha M Abdullah.;Al-Shaimaa M Abdel-Naiem.
来源: BMC Rheumatol. 2024年8卷1期34页
to detect the role of procalcitonin, erythrocyte sedimentation rate to c-reactive protein (ESR/CRP) ratio, neutrophils-to-lymphocyte ratio (NLR), and platelets-to-lymphocyte ratio (PLR) in the diagnosis of infection in systemic lupus erythematosus (SLE) patients with fever, their diagnostic value to differentiate between infection and disease activity, and their correlation with disease activity.
2100. Longitudinal analysis of serum urate in prediabetic phase.
作者: Javier Marrugo.;Leah M Santacroce.;Misti L Paudel.;Sho Fukui.;Sara K Tedeschi.;Daniel H Solomon.
来源: Rheumatology (Oxford). 2024年63卷11期2976-2980页
Despite the well-established association between prediabetes and hyperuricaemia, knowledge about serum urate (SU) trends during the prediabetic phase is limited. Therefore, we aimed to assess the longitudinal changes of SU in individuals with prediabetes.
|